Tocqueville Asset Management L.P. Blueprint Medicines Corp Transaction History

Tocqueville Asset Management L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 14, 2020	SELL	$66.73 - $82.59 $522,495 - $646,679	-7,830 Closed	0 $0
Q3 2019 Oct 31, 2019	BUY	$72.9 - $101.41 $47,385 - $65,916	650 Added 9.05%	7,830 $575,000
Q2 2019 Jul 31, 2019	BUY	$73.54 - $97.8 $528,017 - $702,204	7,180 New	7,180 $677,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.